FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3022757177> ?p ?o ?g. }

• W3022757177 endingPage "1732" @default.
• W3022757177 startingPage "1725" @default.
• W3022757177 abstract "Intravenous daratumumab is approved for the treatment of multiple myeloma. In Part 1 of the PAVO study, a mix-and-deliver subcutaneous formulation of daratumumab with recombinant human hyaluronidase PH20 (rHuPH20) was well tolerated, with low rates of infusion-related reactions and similar efficacy to intravenous daratumumab. Part 2 of PAVO evaluated a concentrated, pre-mixed co-formulation of daratumumab and rHuPH20 (DARA SC). Patients with ≥2 prior lines of therapy, including a proteasome inhibitor and immunomodulatory drug, received daratumumab (1800 mg) and rHuPH20 (30,000 U) in 15 mL subcutaneously over 3-5 minutes per the approved intravenous monotherapy dosing schedule. Primary endpoints were daratumumab trough concentration at the end of weekly dosing (just prior to the Cycle 3 Day 1 dose) and safety. Twenty-five patients were enrolled in PAVO Part 2. DARA SC achieved daratumumab trough concentrations similar to or greater than intravenous daratumumab 16 mg/kg. The adverse event profile of DARA SC was consistent with intravenous daratumumab, with no new safety concerns and a lower infusion-related reaction rate. At a median follow-up of 14.2 months, the overall response rate was 52%, median duration of response was 15.7 months, and median progression-free survival was 12.0 months. DARA SC 1800 mg was well tolerated in relapsed/refractory multiple myeloma, with a low infusion-related reaction rate and reduced administration time. Daratumumab serum concentrations following DARA SC were consistent with intravenous dosing, and deep and durable responses were observed. Based on these results, ongoing studies are investigating DARA SC in multiple myeloma and other conditions. (ClinicalTrials.gov identifier: 02519452)." @default.
• W3022757177 created "2020-05-13" @default.
• W3022757177 creator A5006108161 @default.
• W3022757177 creator A5009980783 @default.
• W3022757177 creator A5011827756 @default.
• W3022757177 creator A5020989412 @default.
• W3022757177 creator A5027858059 @default.
• W3022757177 creator A5028707750 @default.
• W3022757177 creator A5029035458 @default.
• W3022757177 creator A5029159537 @default.
• W3022757177 creator A5049230560 @default.
• W3022757177 creator A5054952877 @default.
• W3022757177 creator A5058050298 @default.
• W3022757177 creator A5058953086 @default.
• W3022757177 creator A5063858836 @default.
• W3022757177 creator A5069712875 @default.
• W3022757177 creator A5070014603 @default.
• W3022757177 creator A5077897003 @default.
• W3022757177 creator A5083639923 @default.
• W3022757177 date "2020-04-30" @default.
• W3022757177 modified "2023-10-14" @default.
• W3022757177 title "Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO)" @default.
• W3022757177 cites W1585625390 @default.
• W3022757177 cites W1902692042 @default.
• W3022757177 cites W2003734726 @default.
• W3022757177 cites W2005475183 @default.
• W3022757177 cites W2015186160 @default.
• W3022757177 cites W2044436186 @default.
• W3022757177 cites W2141502099 @default.
• W3022757177 cites W2229483068 @default.
• W3022757177 cites W2400276917 @default.
• W3022757177 cites W2402003835 @default.
• W3022757177 cites W2443548094 @default.
• W3022757177 cites W2510398184 @default.
• W3022757177 cites W2512106959 @default.
• W3022757177 cites W2528329272 @default.
• W3022757177 cites W2551291014 @default.
• W3022757177 cites W2553693801 @default.
• W3022757177 cites W2557319359 @default.
• W3022757177 cites W2588591261 @default.
• W3022757177 cites W2688500010 @default.
• W3022757177 cites W2760963340 @default.
• W3022757177 cites W2784140703 @default.
• W3022757177 cites W2794728342 @default.
• W3022757177 cites W2806982164 @default.
• W3022757177 cites W2890385438 @default.
• W3022757177 cites W2890754880 @default.
• W3022757177 cites W2892230801 @default.
• W3022757177 cites W2905082484 @default.
• W3022757177 cites W2954589716 @default.
• W3022757177 cites W2981183731 @default.
• W3022757177 doi "https://doi.org/10.3324/haematol.2019.243790" @default.
• W3022757177 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8168515" @default.
• W3022757177 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32354874" @default.
• W3022757177 hasPublicationYear "2020" @default.
• W3022757177 type Work @default.
• W3022757177 sameAs 3022757177 @default.
• W3022757177 citedByCount "24" @default.
• W3022757177 countsByYear W30227571772020 @default.
• W3022757177 countsByYear W30227571772021 @default.
• W3022757177 countsByYear W30227571772022 @default.
• W3022757177 countsByYear W30227571772023 @default.
• W3022757177 crossrefType "journal-article" @default.
• W3022757177 hasAuthorship W3022757177A5006108161 @default.
• W3022757177 hasAuthorship W3022757177A5009980783 @default.
• W3022757177 hasAuthorship W3022757177A5011827756 @default.
• W3022757177 hasAuthorship W3022757177A5020989412 @default.
• W3022757177 hasAuthorship W3022757177A5027858059 @default.
• W3022757177 hasAuthorship W3022757177A5028707750 @default.
• W3022757177 hasAuthorship W3022757177A5029035458 @default.
• W3022757177 hasAuthorship W3022757177A5029159537 @default.
• W3022757177 hasAuthorship W3022757177A5049230560 @default.
• W3022757177 hasAuthorship W3022757177A5054952877 @default.
• W3022757177 hasAuthorship W3022757177A5058050298 @default.
• W3022757177 hasAuthorship W3022757177A5058953086 @default.
• W3022757177 hasAuthorship W3022757177A5063858836 @default.
• W3022757177 hasAuthorship W3022757177A5069712875 @default.
• W3022757177 hasAuthorship W3022757177A5070014603 @default.
• W3022757177 hasAuthorship W3022757177A5077897003 @default.
• W3022757177 hasAuthorship W3022757177A5083639923 @default.
• W3022757177 hasBestOaLocation W30227571771 @default.
• W3022757177 hasConcept C126322002 @default.
• W3022757177 hasConcept C141071460 @default.
• W3022757177 hasConcept C143998085 @default.
• W3022757177 hasConcept C197934379 @default.
• W3022757177 hasConcept C2776364478 @default.
• W3022757177 hasConcept C2777288759 @default.
• W3022757177 hasConcept C2777478702 @default.
• W3022757177 hasConcept C2781119759 @default.
• W3022757177 hasConcept C31760486 @default.
• W3022757177 hasConcept C535046627 @default.
• W3022757177 hasConcept C71924100 @default.
• W3022757177 hasConcept C98274493 @default.
• W3022757177 hasConceptScore W3022757177C126322002 @default.
• W3022757177 hasConceptScore W3022757177C141071460 @default.
• W3022757177 hasConceptScore W3022757177C143998085 @default.
• W3022757177 hasConceptScore W3022757177C197934379 @default.
• W3022757177 hasConceptScore W3022757177C2776364478 @default.

• next